Clinical Trials Directory

Trials / Completed

CompletedNCT02147548

Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly

Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly. A Monocentric, Randomized, Cross-over, Double-blind Clinical Study Versus Placebo

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
31 (actual)
Sponsor
Biocodex · Industry
Sex
All
Age
65 Years – 75 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the effects of etifoxine (an anxiolytic) compared to lorazepam (a benzodiazepine anxiolytic) on vigilance and cognitive functions in the elderly.

Conditions

Interventions

TypeNameDescription
DRUGetifoxine
DRUGlorazepam
DRUGPlacebo

Timeline

Start date
2013-12-01
Primary completion
2015-10-01
Completion
2015-10-01
First posted
2014-05-26
Last updated
2016-07-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02147548. Inclusion in this directory is not an endorsement.

Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly (NCT02147548) · Clinical Trials Directory